8-K: Alnylam Achieves 2025 Profitability, Strong Revenue Growth

Alnylam Pharmaceuticals reported robust fourth quarter and full year 2025 financial results, achieving GAAP and non-GAAP profitability driven by significant AMVUTTRA sales and outlining ambitious 2026 pipeline goals.

Summary

• Global Net Product Revenues for the full year 2025 reached $2,987 million, representing 81% growth compared to 2024.
• Global Net Product Revenues for the fourth quarter 2025 were $995 million, representing 121% growth compared to the same period in 2024.
• Achieved GAAP and non-GAAP profitability for the full year 2025, with sustainable growth in operating income expected.
• Launched the 'Alnylam 2030 Strategy' focused on scaling through durable ATTR leadership, long-term sustainable innovation, and exceptional financial results.
• Announced 2026 pipeline goals, including 4 clinical readouts, 3 ongoing pivotal studies, 3 Phase 2 study initiations, and 3+ new IND filings.
• Presented new analyses from the HELIOS-B Phase 3 clinical trial of vutrisiran in ATTR-CM patients, showing significant improvement in cardiac parameters and amyloid regression in 22% of treated patients.
• Initiated Phase 2 clinical trials for ALN-4324 (type 2 diabetes mellitus) and ALN-2232 (obesity and weight management).
• Announced a planned $250 million investment to expand its manufacturing facility in Norton, Massachusetts, for a proprietary siRNA enzymatic-ligation platform (siRELISTM).

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a highly positive report, marked by significant revenue growth, achievement of full-year profitability, and a robust pipeline with clear strategic goals and strong future guidance.

Positives

• Full Year 2025 Global Net Product Revenues reached $2,987 million, an 81% increase from $1,646 million in 2024.
• Fourth Quarter 2025 Global Net Product Revenues were $995 million, a 121% increase from $451 million in Q4 2024.
• Achieved GAAP Net Income of $313.7 million for the full year 2025, a significant improvement from a GAAP Net Loss of $(278.2) million in 2024.
• Achieved Non-GAAP Net Income of $683.6 million for the full year 2025, a significant improvement from a Non-GAAP Net Loss of $(3.1) million in 2024.
• AMVUTTRA global net product revenues grew 189% in Q4 2025 and 138% for FY 2025, driven by increased patient demand, mainly in ATTR-CM in the U.S.
• Total TTR (AMVUTTRA & ONPATTRO) net product revenues grew 151% in Q4 2025 and 103% for FY 2025.
• Total Rare (GIVLAARI & OXLUMO) net product revenues grew 26% in Q4 2025 and 18% for FY 2025.
• Positive clinical data for vutrisiran in ATTR-CM demonstrated significant improvement on multiple functional and structural cardiac parameters, including amyloid regression in 22% of treated patients.
• Expansion of the pipeline with three Phase 3 studies initiated, four proprietary CTAs, and two new programs (ALN-4285 and ALN-4915) advanced into clinical development.
• Planned $250 million investment in a new manufacturing facility (siRELISTM) is expected to meaningfully expand capacity, significantly reduce production costs, and support future launches.
• Cash, cash equivalents, and marketable securities increased to $2.91 billion as of December 31, 2025, from $2.69 billion as of December 31, 2024.

Negatives

• ONPATTRO global net product revenues decreased 44% in Q4 2025 and 32% for FY 2025 compared to the same periods in 2024, primarily due to a decreased number of patients.
• Net revenues from collaborations decreased by $66 million during Q4 2025 compared to Q4 2024, primarily due to a non-recurring milestone revenue recognized from Novartis in Q4 2024.
• Cost of goods sold as a percentage of net product revenues increased to 26.9% in Q4 2025 (from 22.8% in Q4 2024) and to 22.7% for FY 2025 (from 18.6% in FY 2024), primarily due to increased AMVUTTRA sales and associated higher blended royalty rates.
• GAAP Research & Development expenses increased 24% in Q4 2025 and 17% for FY 2025, primarily due to increased clinical trial expenses and employee compensation.
• GAAP Selling, General & Administrative expenses increased 10% in Q4 2025 and 24% for FY 2025, primarily due to higher employee compensation and increased marketing investment for AMVUTTRA.

Risks

• Ability to successfully execute on the Alnylam 2030 strategy.
• Ability to successfully launch, market, and sell approved products globally, including AMVUTTRA.
• Ability to discover and develop novel drug candidates and delivery approaches and successfully demonstrate the efficacy and safety of product candidates.
• Pre-clinical and clinical results for product candidates may differ from expectations.
• Actions or advice of regulatory agencies and ability to obtain and maintain regulatory approval, as well as favorable pricing and reimbursement.
• Delays, interruptions, or failures in the manufacture and supply of marketed products or product candidates.
• Obtaining, maintaining, and protecting intellectual property.
• Ability to manage growth and operating expenses through disciplined investment in operations.
• Ability to maintain strategic business collaborations.
• Dependence on third parties for the development and commercialization of certain products, including Roche, Novartis, Sanofi, and Regeneron.
• Outcome of litigation and government investigations, and the risk of future litigation and government investigations.
• Unexpected expenditures.

Future Outlook

Alnylam expects continued strong growth in 2026, with total net product revenues projected between $4.9 billion and $5.3 billion, representing 64%-77% growth over 2025. The company plans to advance its pipeline with 4 clinical readouts, 3 ongoing pivotal studies, 3 Phase 2 study initiations, and 3+ new IND filings. The 'Alnylam 2030 Strategy' aims for global TTR leadership, sustainable innovation, and exceptional financial results.

Management Comments

• "2025 was a year of key accomplishments for Alnylam, highlighted by the landmark approval of AMVUTTRA for ATTR-CM in the U.S., which drove total net product revenues of nearly $3 billion, or 81% growth year-over-year, and propelled us to profitability." Yvonne Greenstreet, M.D., Chief Executive Officer.
• "We also achieved great progress across our portfolio, initiating three Phase 3 studies, expanding our pipeline with four proprietary CTAs, and launching a potential best-in-class enzymatic ligation-based RNAi manufacturing platform." Yvonne Greenstreet, M.D., Chief Executive Officer.
• "By pursuing these ambitious goals [Alnylam 2030], we believe Alnylam will drive substantial patient impact by addressing serious unmet medical needs around the world and create substantial long-term shareholder value." Yvonne Greenstreet, M.D., Chief Executive Officer.

Industry Context

StockSavvy.ai notes that Alnylam's strong performance, particularly with AMVUTTRA, positions it as a leader in the RNAi therapeutics space, a rapidly advancing frontier in drug development. The strategic focus on ATTR leadership and pipeline expansion aligns with broader industry trends towards specialized therapies for rare and complex diseases, leveraging advanced genetic technologies. The investment in a new manufacturing platform indicates a commitment to scaling production and reducing costs, which is crucial for long-term competitiveness in the biopharmaceutical sector.

Comparison to Industry Standards

• Alnylam's 81% year-over-year net product revenue growth for FY 2025 significantly outperforms typical growth rates for established pharmaceutical companies, indicating strong market penetration and demand for its RNAi therapeutics, especially AMVUTTRA.
• Achieving GAAP profitability for the full year 2025 is a critical milestone, demonstrating successful commercialization and operational efficiency, which is often a challenge for biotech companies in earlier stages of product launches.
• The planned $250 million investment in a proprietary siRNA enzymatic-ligation manufacturing facility (siRELISTM) represents a substantial commitment to in-house production capabilities, potentially offering a competitive advantage in cost and supply chain control compared to companies reliant on contract manufacturing organizations.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, achievement of profitability, robust pipeline, and positive future outlook, potentially leading to increased shareholder value.
• Patients: Positive impact through the continued development and commercialization of RNAi therapeutics addressing serious unmet medical needs, such as AMVUTTRA for ATTR-CM.
• Employees: Potential positive impact from company growth, pipeline expansion, and investment in manufacturing, which may lead to job creation and career opportunities.
• Customers (Healthcare Providers): Continued access to innovative RNAi therapeutics for their patients.
• Suppliers: Increased demand for manufacturing and R&D related supplies due to facility expansion and pipeline advancement.
• Creditors: Improved financial health and profitability enhance the company's creditworthiness.

Next Steps

• Host an investor webinar on March 24, 2026, to highlight progress for ATTR-CM patients and the long-term growth and durability of its flagship TTR franchise.
• Complete enrollment in the cAPPricorn-1 Phase 2 clinical trial of mivelsiran in patients with cerebral amyloid angiopathy in the first half of 2026.
• Initiate a Phase 2 clinical trial of mivelsiran in patients with Alzheimer's disease in the first half of 2026.
• Initiate a Phase 2 clinical trial of ALN-6400 in a second bleeding disorder in the first half of 2026.
• Announce clinical de-risking data from several pipeline programs, including ALN-6400, ALN-HTT02, and ALN-2232, in the second half of 2026.
• Continue executing on the Alnylam 2030 Strategy to drive substantial patient impact and create long-term shareholder value.

Key Dates

Recommendation

Alnylam's full-year 2025 results demonstrate a pivotal shift to profitability, driven by exceptional growth in its flagship AMVUTTRA product. The company's 2026 guidance projects continued robust revenue expansion (64-77% growth), supported by a deep and advancing pipeline and strategic investments in manufacturing. The positive clinical data for vutrisiran in ATTR-CM further solidifies its market position. Despite some product-specific declines (ONPATTRO) and increased operating expenses, the overall trajectory, strong cash position, and clear strategic vision for 'Alnylam 2030' suggest significant long-term value creation potential, making it a compelling 'strong buy' for investors.

Keywords

Alnylam, ALNY, RNAi therapeutics, AMVUTTRA, ONPATTRO, GIVLAARI, OXLUMO, ATTR-CM, hATTR-PN, Acute Hepatic Porphyria, Primary Hyperoxaluria Type 1, Financial Results, Q4 2025, Full Year 2025, Profitability, Pipeline, Clinical Trials, Manufacturing, Biopharmaceutical, Rare Disease, Cardiology, Neurology, Metabolic Disorders